Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report

doi:10.4251/wjgo.v16.i2.557

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1774)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1071

Figures (1-3)

122

Tables (1-1)

121

Sum=1390

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

233

Sum=324

Feb 15, 2024 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Feb 15, 2024; 16(2): 557-562
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.557

Full Size Figure Download Figure

Figure 2 Clinical course of the patient. Bilirubin and carcinoembryonic antigen levels markedly decreased after four cycles of panitumumab monotherapy. CEA: Carcinoembryonic antigen.

Citation: Tsurui T, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T. Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report. World J Gastrointest Oncol 2024; 16(2): 557-562
URL: https://www.wjgnet.com/1948-5204/full/v16/i2/557.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i2.557